Text Size

The Role of the Vagus Nerve in Tumor-to-Brain Communication in Lung Cancer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00397124
First received: November 7, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted
  Purpose

the aim of this study is to measure brain metabolism in patients with lung cancer.FDG uptake in the brain in patients with malignant tumors will be compared to the amount of tracer activity found in patients who have benign pulmonary process. if differences between the brain uptake of FDG in the two groups will be found, further assessment will be performed in order to evaluate if such differences could be attributed and specifically localized to the brain regions innervated by the vagus


Condition Intervention
Lung Cancer
 Device: PET/CT imaging

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Does the Vagus Nerve Play a Role in Tumor-to-Brain Communication? a Preliminary Study in Patients With Newly Diagnosed Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • the impact of the imaging modality on patients management

Secondary Outcome Measures:
  • the impact of the imaging modality on patients management

Estimated Enrollment: 40
Study Start Date: April 2002
  Eligibility

Ages Eligible for Study:   35 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with SPN referred for routine whole body FDG-PET imaging
  • patients with NSCLC and patients with no evidence of lung cancer on further follow up

Exclusion Criteria:

  • patients with a clinical history of vagotomy, abdominal surgery. brain tumor, brain trauma or CVA. or those with a systemic inflammatory disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00397124

Contacts
Contact: Alex Frenkel, Ph.D 972-4-8543009 a_frenkel@rambam.health.gov.il

Locations
Israel
Rambam Medical Center Recruiting
Haifa, Israel
Contact: Alex Frenkel, Ph.D     972-4-8543009     a_frenkel@rambam.health.gov.il    
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Ora Israel, MD Rambam Health Care Campus
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00397124     History of Changes
Other Study ID Numbers: vagusCTIL
Study First Received: November 7, 2006
Last Updated: November 7, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013